Epitope-specific Enhancement of Antigen Presentation by Invariant Chain

By Frank Momburg, Serge Fuchs,* Johannes Drexler, Robert Busch, Markus Post, Günter J. Hämmerling, and Luciano Adorini†

From the Tumor Immunology Program, German Cancer Research Center, D-69120 Heidelberg, Germany; *Preclinical Research, Sandoz Pharma Ltd., CH-4002 Basel, Switzerland; and †Roche Milano Ricerche, I-20132 Milano, Italy

Summary

The MHC class II-associated invariant chain (Ii) is involved in the intracellular sorting of class II molecules to the endocytic pathway where peptides from processed exogenous antigens are bound, and thereby Ii is thought to enhance antigen presentation. Here we demonstrate that presentation of only one out of five epitopes of a given antigen is augmented by Ii. We have compared the presentation of five different epitopes derived from hen egg white lysozyme (HEL) to $\text{A}_2^k$-restricted T hybridomas by rat-2 fibroblasts transfected with $\text{A}_2^k$ and $\text{A}_2^b$ (RKK) and RKK cells supertransfected with the mouse invariant chain (RKKI). Only the presentation of the HEL epitope 46-61 was enhanced whereas the presentation of the HEL epitopes 25-43, 34-45, 112-124, and 116-129 was unchanged or even slightly diminished in RKKI cells. The presentation of the epitopes 25-43 and 34-45 was virtually insensitive to the lysosomotropic reagent chloroquine. Brefeldin A (BFA), which inhibits protein egress from the endoplasmic reticulum, blocked the presentation of all epitopes tested in RKKI cells. In contrast, in Ii-negative RKK cells only the presentation of the epitope HEL(46-61) was inhibited by BFA and the presentation of the epitopes 25-43 and 34-45 was only slightly impaired. These findings suggest that Ii may target class II molecules to selected endosomal subcompartments involved in the processing of different peptides derived from an endocytosed antigen. As a result, the enhancement of the class II-restricted presentation in Ii expressing cells appears to be epitope specific rather than antigen specific.

The MHC class II-associated invariant chain has been ascribed a number of different functions. One proposed role is to provide a sorting signal for the intracellular transport of class II molecules (1). In HeLa cells, transport of class II molecules to the endocytic compartment was observed only when Ii was coexpressed (2, 3). Ii probably directs class II molecules to a late endosomal compartment (4). A second role has been suggested by biochemical studies indicating that Ii can block the peptide binding to class II $\alpha\beta$ dimers (5, 6). Thus, Ii may prevent peptide loading onto class II molecules in preendosomal compartments. A third possible role of Ii is to act as a chaperone in the assembly and folding of class II molecules, and in their egress from the endoplasmic reticulum (7, 8).

These proposed functions suggest that Ii may facilitate the class II-restricted presentation of exogenous antigens to T cells. For Ltk- cells transfected with mouse class II genes in the presence or absence of Ii, Ii expression was reported to enhance the presentation of some antigens like the complement component C5 (9), hen egg lysozyme or measles virus hemagglutinin (10), but not of other antigens like ovalbumin or pork insulin (11). The crucial role of Ii in the presentation of certain antigens was further demonstrated with splenocytes from mice lacking the Ii gene (12). Recently, it was shown that the alternatively spliced Ii gene product p41 plays a role in the enhanced presentation of some antigens (13). Utilizing rat-2 fibroblasts expressing $\text{A}_2^k$ in the presence or absence of Ii, we previously reported that presentation of HEL but not of ribonuclease A (RNase) was enhanced in the presence of Ii (14). Extending these findings we now show that the facilitating function of Ii is restricted to only one out of five epitopes derived from processing of HEL, suggesting that Ii may be involved in the fine tuning of the immune response to exogenous antigens.

Materials and Methods

Transfectants. Rat-2 fibroblasts transfected with cDNA con-
structs coding for the α and β chain of Aβ (RKK) have been described (14). Supertransfection with genomic DNA coding for murine li was performed as described (14). RKKI clone 4 which expresses high amounts of li was used in this study. li expression was determined by cytoplasmic immunoperoxidase staining and by immunoprecipitation. The T cell hybridomas 2B6.31 (15), 1C5.1, 2D4.1 (16), 3A9 (17), 2C8.4 (18), and TSL2 (19) have been described. The T cell hybridomas 3B11.1, 4G4.1, 1G5.1, 2B5.1, and 1B9.1 were generated for the present study and characterized as described (18).

Immunoprecipitations. Immunoprecipitations were performed as described (14). Briefly, 3 × 10^6 cells were labeled for 1 h with 100 μCi of a mixture of 80% [35S]methionine and [35S]cysteine (ICN-Flow, Cleveland, OH). The adherent cells were harvested from the dishes with TBS lysis buffer containing 1% NP-40. The lysates were precleared with Protein A-soluble (Sigma Chemical Co., St. Louis, MO) and a mixture of normal rat and mouse sera. For immunoprecipitations, Protein A-Sepharose beads (Pharmacia, Inc., Piscataway, NJ) preabsorbed with monoclonal antibodies were added to the lysates for 2 h. Aβ molecules were precipitated with mAb H116-32. To precipitate li, mAb In1 followed by FITC-conjugated goat anti-rat Ig (Southern Biotechnology, Inc., Birmingham, AL).

Intracellular staining with mAb H116-32 was followed by two washes. Class II expression was determined by cytoplasmic immunoperoxidase staining and by intracellular cytofluorometry (Fig. 1 b). The level of Aβ cell surface expression was slightly lower in the RKKI clone used in this study than in RKK parental cells (Fig. 1 b), possibly due to intrinsic clonal variability of these cells. Although li is supposed to facilitate the egress of class II molecules from the endosome, li expression was determined in the same experiment using saturating amounts of FITC-conjugated mAb H116-32. 5000 cells per sample were analyzed for median fluorescence channel (MFC) intensity on a FACScan flow cytometer. Subsequently the cells were stained with mAb In1 followed by FITC-conjugated goat anti-rat Ig (Southern Biotechnology, Inc., Birmingham, AL).

Figure 1. (a) Immunoprecipitation of Aβ and li molecules from metabolically labeled RKK and RKKI cells. For control, untransfected rat-2 cells (R) were used. First Aβ was precipitated with mAb H116-32 (anti-1-Aβ), then li was precipitated from the same lysates with mAb In1 (anti-li). The positions of the α and β chains of Aβ and of the p31 form of li are indicated. li coprecipitates with Aβ in RKKI cells but is absent in RKK cells. As visible for the β chain of Aβ, class II molecules are more rapidly processed into higher glycosylated forms in the presence of li. After cleaving of class II molecules, high amounts of free li were recovered from RKKI cells. (b) Surface immunofluorescence staining of RKK and RKKI cells for Aβ with mAb H116-32. li was intracellularly stained with mAb In1 after permeabilization of cells with saponin. (c) Indistinguishable binding of biotinylated peptide HEL(46-61) to RKK and RKKI cells. Cells were incubated with labeled amounts of biotinyl-HEL(46-61) and stained with two layers of avidin-FITC sandwiched by biotinylated anti-avidin Ab. The MFC ratios shown represent relative peptide binding, normalized for differences in class II expression that were determined in the same experiment (see Materials and Methods).
Table 1. Activation of A\textsuperscript{b}-restricted T Cell Hybridomas by Ii-negative RKK Cells and by Ii-positive RKKI Cells

| Hybridoma | Peptide | Restriction | EC\textsubscript{50} for protein (\mu M) | Ratio EC\textsubscript{50} RKK/RKKI | EC\textsubscript{50} for peptide (\mu M) |
|-----------|---------|-------------|-----------------------------------------|-------------------------------------|-------------------------------------|
| 2B6.31    | HEL 25-43 | A\textsuperscript{b} | 220 | 270 | 0.82 | 5.00 | 13.00 |
| 3B11.1    | HEL 34-45 | A\textsuperscript{b} | 60 | 100 | 0.60 | 3.00 | 6.00 |
| 1C5.1     | HEL 46-61 | A\textsuperscript{b} | 150 | 2 | 75.00 | 0.05 | 0.13 |
| 4G4.1     | HEL 46-61 | A\textsuperscript{b} | 45 | 12 | 3.75 | 0.05 | 0.13 |
| 1G5.1     | HEL 46-61 | A\textsuperscript{b} | 170 | 40 | 4.25 | 0.04 | 0.13 |
| 2B5.1     | HEL 46-61 | A\textsuperscript{b} | 200 | 7 | 28.57 | 0.30 | 0.80 |
| 3A9       | HEL 46-61 | A\textsuperscript{b} | 100 | 3 | 33.33 | 0.50 | 0.80 |
| 2D4.1     | HEL 112-124 | A\textsuperscript{b} | 500 | 600 | 0.83 | 0.10 | 0.40 |
| 2C8.4     | HEL 116-129 | A\textsuperscript{b} | 500 | 500 | 1.00 | 0.13 | 0.50 |
| 1B9.1     | HEL 116-129 | A\textsuperscript{b} | 150 | 300 | 0.50 | 0.07 | 0.30 |
| TS1.2     | RNase 43-56 | A\textsuperscript{b} | 0.5 | 2 | 0.25 | 1.50 | 2.00 |

The responsiveness of T cell hybridomas to protein antigen (HEL or RNase) or to the indicated synthetic peptide presented by RKK or RKKI cells was estimated by the antigen concentration (\mu M) giving 50% of the maximal response (EC\textsubscript{50}). A representative experiment out of three performed with similar results is shown.

![Graph a](image1)

![Graph b](image2)

Figure 2. Efficiency of the presentation of the A\textsuperscript{b}-restricted HEL epitopes 46-61 and 25-43 by Ii-negative and Ii-positive rat-2 cells. RKK cells (open symbols) or RKKI cells (closed symbols), 2.5x10\textsuperscript{4} well, were incubated for 24 h with graded concentrations of HEL (squares) or the appropriate peptide (triangle) and 5x10\textsuperscript{4} well T hybridoma cells. For control fixed RKKI cells (circles) were incubated with HEL. In (a) hybridoma 3A9 (HEL 46-61) and in (b) hybridoma 2B6.31 (HEL 25-43) was used. IL-2 production was determined by \textsuperscript{[3]H}thymidine incorporation into CTLL-2 cells. Data are presented as mean cpm from triplicate cultures.
cells at an about 30-fold lower HEL concentration than RKK cells, but that at high HEL concentrations RKK stimulated almost as well as RKKI. For the hybridomas 1C5.1, 2B5.1, and 3A9, the EC50 ratios were about 10 to 20 times greater than for the hybridomas 4G4.1 and 1G5.1. This difference did not correlate with the sensitivity of the hybridomas as determined by their responses to exogenously added peptide (Table 1). Exogenously added peptide was always presented somewhat more efficiently by RKK cells than by RKKI cells. This difference probably reflects the slightly higher level of Aκ expression in RKK because the degree of loading with peptide was similar for both cell lines (Fig. 1 c). The fine specificities of these hybridomas for shorter peptides within the sequence 46-61 have not been compared. Thus, it seems possible that the differences in the EC50 ratios are due to differentially enhanced presentation of subdeterminants of epitope 46-61.

Using the hybridomas 2B6.31 (Fig. 2 b) and 3B11.1 recognizing the overlapping HEL epitopes 25-43 and 34-45, respectively, an EC50 ratio close to unity was found indicating that ιi did not facilitate the presentation of these epitopes. The hybridomas 2D4.1, 2C8.4, and 1B9.1 recognizing the overlapping COOH-terminal epitopes HEL 112-124 and 116-129, respectively, showed EC50 ratios <1.0 demonstrating the lack of enhancement for these epitopes by ιi. For comparison, the hybridoma TS1.2 specific for the RNase epitope 43-56 was included (Table 1). RKK cells were clearly superior to RKKI cells in the presentation of RNase (EC50 ratio 0.25).

The lysosomotropic reagent chloroquine interferes with the acidification of the endosomal compartment. For selected

![Figure 3. Chloroquine sensitivity of the presentation of HEL by RKK and RKKI cells.](image)

![Figure 4. Brefeldin sensitivity of the presentation of HEL by RKK and RKKI cells.](image)
hybridomas we studied the effect of chloroquine on the presentation of HEL epitopes by RKK and RKKI cells (Fig. 3). Interestingly, the presentation of the epitope 34-45 was not inhibited by titrated doses of chloroquine in RKK cells, and showed a slight inhibition only at 300 μM in RKKI cells. Similarly, increasing doses of chloroquine had little effect on the presentation of epitope 25-43. In contrast, chloroquine clearly inhibited the presentation of the epitopes 46-61 and 116-129 in both RKK and RKKI cells. For the four epitopes studied, presentation by RKKI cells was always somewhat more sensitive to chloroquine than presentation by RKK cells (see Fig. 3 b). This is in agreement with the observation that chloroquine inhibits the proteolytic removal of Ii from class II αβ dimers before their transport to the cell surface (21).

The fungal metabolite brefeldin A blocks the vesicular transport from the endoplasmic reticulum. In addition, BFA was reported to induce the fusion of early endosomes with the trans-Golgi network (22). However, the extent of impairment induced by BFA on the transport and the degradation of endocytosed proteins is controversial (22, 23). We have studied the effect of BFA on the presentation of the HEL epitopes 25-43, 34-45, and 46-61 (Fig. 4). When RKK cells were used as APC, the presentation of the epitopes 25-43 and 34-45 was inhibited by only 30-40% even at the highest BFA doses used, whereas the presentation of epitope 46-61 was almost completely blocked. In a previous study presentation of epitope 116-129 by LK-35.2 B cells was also inhibited by BFA (24). In RKKI cells, the presentation of the three epitopes tested was clearly inhibited by high doses of BFA, although the presentation of epitopes 25-43 and 34-45 was inhibited to a lesser extent at concentrations lower than 30 μM BFA.

Out of the five A K-restricted HEL epitopes studied here, only the presentation of the epitope 46-61 was enhanced in the presence of an invariant chain. This may indicate that the Ii-mediated targeting of the class II/Ii complex to a prelysosomal compartment (4) is responsible for the selective enhancement in the presentation of HEL(46-61). The presentation of this epitope, and of 116-129, was clearly more sensitive to chloroquine than the epitopes 25-43 and 34-45. In line with these results are observations showing that the chloroquine-sensitive environment of lysosomes is required for the initial reduction of disulfide bonds in HEL, and subsequent presentation of the epitope 46-61 (25, 26). The HEL epitopes 34-45 and 25-43 are virtually insensitive to chloroquine, suggesting processing in early endocytic compartments, where protein breakdown may be less dependent on acidic pH, or processing by endoproteinases relatively resistant to increased pH.

Alternatively, the loading of peptides onto class II molecules, rather than their cleavage, could be differentially influenced by chloroquine. This would be consistent with the observation that the binding of peptide 34-45 to fixed A K-expressing cells is unchanged between pH 5.0 to pH 7.4, whereas the binding of peptide 46-61 shows an optimum at pH 5.5 (27). Utilizing purified A K molecules, Sette et al., found a binding optimum for HEL(46-61) at pH 4.5 (28).

In RKK cells, the presentation of peptide 46-61 was significantly more sensitive to BFA treatment than the presentation of the peptides 25-43 and 34-45. In line with previous observations (24, 29) this may imply that the peptide 46-61 binds to A K in an endosomal subcompartment fed with newly synthesized class II molecules which are retained in the ER in the presence of BFA. In contrast, the peptides 25-43 and 34-45 seem to have access to a pool of preexisting class II molecules that may arise from internalization of unloaded molecules from the surface. In RKKI cells the presentation of the three HEL peptides, 25-43, 34-45, and 46-61, was clearly sensitive to BFA, indicating presentation by newly synthesized class II molecules.

In conclusion, it appears that the augmenting effect of Ii is actually epitope specific rather than simply antigen specific (9, 10, 14). In addition, distinct pathways of presentation for different HEL epitopes exist. The epitope 46-61 is exclusively or predominantly bound by newly synthesized class II molecules and its presentation is highly chloroquine sensitive, whereas in the absence of Ii the epitopes 25-43 and 34-45 can be presented by a pool of preexisting class II or, in the presence of Ii, also by newly synthesized class II molecules. The precise rules controlling preferential presentation of particular epitopes from the same protein antigen by different pathways remain to be explored.

This work was supported by DFG grant Mo 389/2-1.

Address correspondence to Dr. Frank Momburg, FSP Tumorimmunologie, DKFZ, Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany.

Received for publication 25 January 1993 and in revised form 14 June 1993.

References

1. Bakke, O., and B. Dobberstein. 1990. MHC class II-associated invariant chain contains a sorting signal for endosomal compartments. Cell. 63:707.

2. Lotteau, V., L. Teyton, A. Peleraux, T. Nilsson, L. Karlsson, S.L. Schmid, V. Quaranta, and P.A. Peterson. 1990. Intracellular transport of class II MHC molecules directed by invariant chain. Nature (Lond.). 348:600.

3. Lamb, C.A., J.W. Yewdell, J.R. Bennink, and P. Cresswell. 1991. Invariant chain targets HLA class II molecules to acidic endosomes containing internalized influenza virus. Proc. Natl.
11. Peterson, M., and J. Miller. 1990. Invariant chain influences in the Golgi complex for transport to lysosomal compartments. *Nature (Lond.)* 349:669.

5. Roche, P.A., and P. Cresswell. 1990. Invariant chain association with HLA-DR molecules inhibits immunogenic peptide binding. *Nature (Lond.)* 345:615.

6. Teyton, L., D. O'Sullivan, P.W. Dickson, V. Lotteau, A. Sette, P. Fink, and P.A. Peterson. 1990. Invariant chain distinguishes between the exogenous and endogenous antigen presentation pathways. *Nature (Lond.)* 348:39.

7. Layet, C., and R.N. Germain. 1991. Invariant chain promotes the processing of poorly expressed, haplotype-mismatched class II major histocompatibility complex AAβ dimers from the endoplasmic reticulum/cis-Golgi compartment. *Proc. Natl. Acad. Sci. USA.* 88:2346.

8. Anderson, M., and J. Miller. 1992. Invariant chain can function as a chaperone protein for class II major histocompatibility complex molecules. *Proc. Natl. Acad. Sci. USA.* 89:2282.

9. Stockinger, B., U. Pessara, R.H. Lin, J. Habicht, M. Grez, and N. Koch. 1989. A role of IA-associated invariant chains in antigen processing and presentation. *Cell.* 56:683.

10. Bertolino, P., P. Forquet, S. Pont, N. Koch, D. Gerlier, and C. Rabourdin-Combe. 1991. Correlation between invariant chain expression level and capability to present antigen to MHC class II-restricted T cells. *Int. Immunol.* 3:435.

11. Peterson, M., and J. Miller. 1990. Invariant chain influences the immunological recognition of MHC class II molecules. *Nature (Lond.)* 345:172.

12. ViviUe, S., J. Neefjes, V. Lotteau, A. Dierich, M. Lemeur, H. Ploegh, C. Benoist, and D. Mathis. 1993. Mice lacking the MHC class-II associated invariant chain. *Cell.* 72:635.

13. Peterson, M., and Miller, J. 1992. Antigen presentation enhanced by the alternatively spliced invariant chain gene product p41. *Nature (Lond.)* 357:596.

14. Nadimi, F., J. Moreno, F. Momburg, A. Heuser, S. Fuchs, L. Adorini, and G.J. Hämmerling. 1991. Antigen presentation of hen egg-white lysozyme but not of ribonuclease A is augmented by the major histocompatibility complex class II-associated invariant chain. *Eur. J. Immunol.* 21:1255.

15. Adorini, L., J. Moreno, F. Momburg, G.J. Hämmerling, J.-C. Guéry, A. Valli, and S. Fuchs. 1991. Exogenous peptides compete for the presentation of endogenous antigens to major histocompatibility complex II-restricted T cells. *J. Exp. Med.* 174:945.

16. Guéry, J.-C., A. Sette, J. Leighton, A. Dragomir, and L. Adorini. 1992. Selective immunosuppression by administration of major histocompatibility complex (MHC) class II binding–peptides. I. Evidence for in vivo MHC blockade preventing T cell activation. *J. Exp. Med.* 175:1345.

17. Allen, P.M., and E.R. Unanue. 1984. Differential requirements for antigen processing by macrophages for lysozyme–specific T cell hybridomas. *J. Immunol.* 132:1077.

18. Adorini, L., E. Appella, G. Doria, and Z.A. Nagy. 1988. Mechanisms influencing the immunodominance of T cell determinants. *J. Exp Med.* 168:2091.

19. Lorenz, R.G., A.N. Tyler, and P.M. Allen. 1988. T cell recognition of bovine ribonuclease: self/non-self discrimination at the level of binding to the IAα molecule. *J. Immunol.* 141:4124.

20. Busch, R., and J.B. Rothbard. 1990. Detection of peptide–MHC class II complexes on the surface of intact cells. *J. Immunol. Methods.* 134:1.

21. Nowell, J., and V. Quaanta. 1985. Chloroquine affects biosynthesis of IA molecules by inhibiting dissociation of invariant (γ) chains from αβ dimers in B cells. *J. Exp. Med.* 162:1371.

22. Lippincott-Schwartz, J., L. Yuan, C. Tipper, M. Amherdt, L. Orci, and R.D. Klausner. 1991. Brefeldin A's effect on endosomes, lysosomes, and the TGN suggest a general mechanism for regulating organelle structure and membrane traffic. *Cell.* 67:601.

23. Wood, S.A., and W.J. Brown. 1992. The morphology but not the function of endosomes and lysosomes is altered by brefeldin A. *J. Cell Biol.* 119:273.

24. Adorini, L., S.J. Ullrich, E. Apella, and S. Fuchs. 1990. Inhibition by brefeldin A of presentation of exogenous protein antigens to MHC class II-restricted T Cells. *Nature (Lond.)* 346:63.

25. Harding, C., D.S. Collins, J.W. Slot, H.J. Geuze, and E.R. Unanue. 1991. Liposome-encapsulated antigens are processed in lysosomes, recycled, and presented to T cells. *Cell.* 64:393.

26. Collins, D.S., E.R. Unanue, and C.V. Harding. 1991. Reduction of disulfide bonds within lysosomes is a key step in antigen processing. *J. Immunol.* 147:4054.

27. Harding, C., R.W. Roof, P.M. Allen, and E.R. Unanue. 1991. Effects of pH and polysaccharides on peptide binding to class II major histocompatibility complex molecules. *Proc. Natl. Acad. Sci. USA.* 88:2740.

28. Sette, A., S. Southwood, D. O'Sullivan, P.C.A. Gaeta, J. Sidney, and H.M. Grez. 1992. Effect of pH on MHC class II–peptide interactions. *J. Immunol.* 148:844.

29. St.-Pierre, Y., and T.H. Watts. 1990. MHC class II-restricted presentation of native protein antigens by B cells is inhabitable by cycloheximide and brefeldin A. *J. Immunol.* 145:812.